Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01959438
Other study ID # Eu-nr 2006-004076-13
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received October 8, 2013
Last updated October 8, 2013
Start date February 2007
Est. completion date June 2018

Study information

Verified date October 2013
Source Karolinska University Hospital
Contact Ola Brodin, MD, PhD
Phone +46 8 6164344
Email ola.brodin@karolinska.se
Is FDA regulated No
Health authority Sweden: Regional Ethical Review BoardSweden: Medical Products Agency
Study type Interventional

Clinical Trial Summary

In vitro studies have demonstrated that sodium selenite in sufficient concentration and during sufficient time have a high tumoricidal capacity. This is found in many human cell types as leukemia cells, mesothelioma and non-small cell lung cancer cells. A minority of cell lines seem to be resistant. The question from a clinical point of view is: Is it possible with respect to toxicity to administer sodium selenite to patients in sufficient dose and during sufficient time to get responses in patients with cancer? We have performed first part of phase-1 study and found MTD of 10.2 mg/m2 if given as 10 daily infusions during 12 days. We have recorded limited anti-tumor effect in this treatment regimen. However, in vitro data suggest that low concentration of continuous exposure for 51 h is much more effective. Now we are planning to continue the phase-I trial with modified protocol.

More specific:

1. Phase I: Find maximal tolerable dose with continuous infusion

2. Phase II: Use MTD and study responses, if any


Description:

- Patients: With advanced malignant disease, any kind, in which all standard treatment has been tried, but still progression. In sufficient good performance status (ps 0-2)to get more treatment: first selenite and immediately afterwards chemotherapy (since an additive or synergistic effect from selenite and chemotherapy has been found).

- Treatment: We have performed the initial study with sodium selenite i.v. daily, 10 treatments during 2 weeks. The week after that response evaluation and then chemotherapy. In each patient, his or her first line chemotherapy treatment is given, since in vitro studies indicate that selenite might reverse resistance. In the modified protocol, a 2 days continuous infusion will be performed.

- Toxicity evaluation (main criteria in phase I): Meeting a doctor once a week during selenite treatment and before each chemotherapy treatment and at End of treatment. Meeting a nurse each treatment day during selenite treatment. Blood samples for liver, kidney, blood and thyroid values. Plasma samples for selenite concentration during treatment.

- Response evaluation (to be: main criteria in phase II and studied also in phase I): CT scan just before and after selenite treatment and after chemotherapy. From May 2011 FDG-PET-CT-scan just before and after selenite treatment. Cytokeratin and cytokeratin fragments evaluation.


Recruitment information / eligibility

Status Recruiting
Enrollment 32
Est. completion date June 2018
Est. primary completion date October 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Advanced malignant tumor disease

- All standard treatments should have been tested, but the disease still progressing.

- In sufficient good performance status to get more treatment

- Informed consent

Exclusion Criteria:

- More than 1 active tumour disease

- Impaired capacity to cooperate

- Serious other disease such as heart or kidney disease that might give extra risk for complications and difficulties to interpret effect of the selenite treatment

- The tumour not possible to evaluate

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Sodium selenite (Introselen)
Intravenous infusion daily for each week day during 2 weeks (10 infusions). After that chemotherapy during 6 weeks. Chemotherapy for each patients is the first line treatment, so chemotherapy differs among patients, with respect to which treatment a patient got as first line.
Sodium selenite
Intravenous treatment as described above. Cohorts of 3 patient are given a fixed dose for daily treatment (started with 0.5 mg/m2) and if no grade 3 or 4 toxicity, a new cohort is started on a higher dose. The dose for next cohort is 50% higher than for the former cohort. If grade 3 or 4 toxicity is found in 1 patient, 3 more patients are included on the same dose and if one more patient has serious toxicity it is considered to high a dose and a dose in between the toxic dose and the one before is tested. Thus if 2 patients in 3-6 tested patients has serious toxicity by a certain dose, this dose is to high and the highest dose is considered the earlier tested dose.

Locations

Country Name City State
Sweden Onkologkliniken, (Dept of Oncology) Södersjukhuset Stockholm

Sponsors (5)

Lead Sponsor Collaborator
Karolinska University Hospital Cancer and Allergy Foundation, Cancerfonden, Cancerföreningen i Stockholm, Stockholms Läns Landsting

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximal tolerable dose (phase I, ongoing) To find which kind and grade of toxicities that are dose-limiting within three year Yes
Secondary Responses Responses are measured essentially by CT scan or PET-CT-scan. During the Phase II study, responses are the primary criteria but in the phase I study toxicity is the main criteria. Two years within the phase I study Yes
See also
  Status Clinical Trial Phase
Recruiting NCT04691349 - CAR-T for r/r Malignant Tumors in Children Early Phase 1
Recruiting NCT04672473 - Treatment of Malignant Tumors With Antigen Peptide-specific DC-CTL Cells and Decitabine Phase 1/Phase 2
Recruiting NCT06080984 - The Application of Novel Oncolytic Virus in Late Stage Solid Tumors Phase 1
Recruiting NCT04991506 - A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors Phase 1
Completed NCT02552004 - Assessment of Intraoperative Probe-based Confocal Laser Endomicroscopy in Digestive and Endocrine Surgery: a Pilot Study N/A
Recruiting NCT05280873 - Pirfenidone Combined With Methylprednisolone Versus Methylprednisolone in the Treatment of CIP Phase 1
Completed NCT06093945 - Effect of Omeprazole on Pharmacokinetics of SHR2554 in Healthy Subjects Phase 1
Completed NCT05592262 - Pharmacokinetic Test of High-fat Diet After Oral Administration of SHR2554 in Healthy Subjects Phase 1
Completed NCT03012945 - Epidural Anesthesia-analgesia and Long-term Outcome N/A
Recruiting NCT04686682 - A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors Phase 1/Phase 2
Recruiting NCT06084767 - 68Ga-TCR-FAPI PET/CT in Patients With Various Types of Cancer N/A
Enrolling by invitation NCT02937246 - Efficacy of Partial Covered Double Bare Metal Stent Compared to Uncovered Double Bare Metal Stent in Malignant Biliary Obstruction N/A
Completed NCT03354741 - Stimulation of Acupuncture Points by Athermic Laser Therapy for the Prevention of Chemotherapy Induced Nausea and Vomiting in Children N/A
Recruiting NCT03931720 - Clinical Research of ROBO1 Specific BiCAR-NK/T Cells on Patients With Malignant Tumor Phase 1/Phase 2
Completed NCT01906632 - Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy N/A
Recruiting NCT05596344 - Long-term Follow-up of Anxiety and Depression in Patients With Malignant Tumors
Active, not recruiting NCT04230200 - Prospective Screening Programme for Malignant Tumors
Completed NCT04730843 - A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors Phase 1
Completed NCT04952766 - Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults Phase 4
Recruiting NCT05781555 - A Study of Diffusing Alpha Radiation Therapy for Target Treatments of Malignant Tumors N/A